A phase I dose escalation study of the combination of dasatinib (BMS-354825) and imatinib in subjects with chronic myeloid leukemia in chronic phase

Trial Profile

A phase I dose escalation study of the combination of dasatinib (BMS-354825) and imatinib in subjects with chronic myeloid leukemia in chronic phase

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 19 Feb 2016

At a glance

  • Drugs Dasatinib (Primary) ; Imatinib
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Feb 2007 Status changed from in progress to withdrawn prior to recruitment.
    • 02 Feb 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top